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estimated from 2006-2012 for all branded and generic monotherapy formulations 
of lisinopril, hydrochlorothiazide, metformin, and levothyroxine. Claims were con-
sidered GDDP-filled if the following criteria were met: the only recorded price paid 
was patient out-of-pocket, and the quantity dispensed and out-of-pocket price-
paid matched published GDDP pharmacy lists, including Walmart, Walgreens, CVS, 
RiteAid, and Kroger. Results: In 2006, the percentage of GDDP-filled prescriptions 
was low: 8.1% (N= 4,472,797) of hydrochlorothiazide, 4.0% (N= 3,880,992) of levo-
thyroxine, 0.01% (N= 4,008) of metformin, and 0.0% of lisinopril. This increased in 
2008, to 2.4% (N= 1,676,928) for metformin, 8.0% (N= 7,107,840) for lisinopril, 16.8% 
(N= 9,024,532) for hydrochlorothiazide, and 18.9% (N= 13,035,972) for levothyroxine. 
In 2009, all medications had a GDDP-filled rate around 20% or greater. The high-
est percentages were seen in 2010: 22.5% (N= 12,033,009) of hydrochlorothiazide, 
25.1% (N= 27,033,234) of levothyroxine, 25.5% (N= 17,593,051) of metformin, and 
29.6% (N= 30,115,329) of lisinopril. By 2012 this decreased, and 19.6% (N= 9,715,614) 
of hydrochlorothiazide, 20.3% (N= 20,813,050) of lisinopril, 22.1% (N= 21,425,226) of 
levothyroxine, and 23.2% (N= 17,842,540) of metformin prescriptions were GDDP-
filled. ConClusions: By 2012, approximately 1 in 5 prescriptions for lisinopril, 
hydrochlorothiazide, metformin, and levothyroxine were filled using a GDDP. As 
they are cash-only, these prescriptions may not be processed via a pharmacy benefit 
manager, and therefore may be missing from insurance claims data.
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objeCtives: ACE inhibitors and ARBs are the cornerstone of therapy for patients 
with hypertension and type 2 diabetes. However, they have been shown to be under-
utilized in elderly patients at high risk for complications. The objectives of this 
study are to 1) assess earlier use of ACEIs/ARBs after incident diabetes diagnosis by 
race/ethnicity groups, and 2) assess whether the use of ACEIs/ARBs improves over 
time after diabetes diagnosis by race/ethnicity group. Methods: We identified fee-
for-service Medicare beneficiaries over the age of 65 with hypertension and newly 
diagnosed T2DM using data from CMS. Treatment use, baseline demographics, and 
other covariates were measured during the 12-month baseline period and the index 
date. Standardized differences were used to assess ACEI/ARB use and a marginal 
effects model with GEE was applied to investigate race/ethnicity differences in 
use rates. Results: 55.5% of 135,923 patients received ACEI/ARB therapy within 3 
months post-diabetes diagnosis (65.2% ACEIs, 38.5% ARBs). ACEI/ARB users within 3 
months after a diabetes diagnosis were younger and had fewer comorbidities, except 
for hyperlipidemia. Compared to non-users, ACEIs/ARBs users had more medica-
tion use. Among the racial/ethnic subgroups, Asians and Hispanics had the highest 
rate of use (59%), followed by Other (56%), White (55%), and Black (53%). Asians and 
Hispanics had 4% and 6% higher RR for use and Blacks had a 2% lower RR compared 
to Whites. Overall, rates of use over time decreased by 1% to 2%, except for a mild 
increase among Blacks (1% to 2%). However, subgroup analyses indicated that the 
decrease could be attributed to patients receiving ACEI/ARB therapy prior to diabetes 
diagnosis. Untreated patients showed an increase in use over time. ConClusions: 
Overall, ACEIs/ARBs are underutilized based on current treatment guidelines and 
use varies significantly across races/ethnicities. Future studies are needed to assess 
reasons for underuse of ACEIs/ARBs to promote better health outcomes.
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objeCtives: The prevalence of statin use in older adults with new onset diabetes 
(T2DM), frequently presenting with co-morbidities and susceptible to poor out-
comes, has not been well characterized. The objective of this study was to exam-
ine and characterize the prevalence of statin use among Medicare patients newly 
diagnosed with diabetes, and to assess statins use gaps by age, gender, and race/
ethnicity as well as those with and without underlying cardiovascular disease 
(CVD). Methods: This was a retrospective cohort study using pharmacy and 
medical claims from CMS. Enrollees with a new T2DM diagnosis (index date) in 
2008, aged 65 years or older, continuously enrolled in Medicare Part A, B, and D, and 
who survived at least 90 days after the index date were included. The prevalence 
of statin use within 90 days of index date across age, gender, race/ethnicity, and 
baseline CVD status was assessed. Multivariable logistic regression was applied to 
investigate the effects of the independent variables. Results: An average statin 
usage rate of 46.3% was found in the 168,800 eligible patients included in the study. 
66,525 patients in the cohort had underlying co-morbid CVD and were more likely 
to receive statins than those without baseline CVD both before (OR= 1.62, 95% CI 
1.58-1.67) and after (OR= 1.23, 95% CI 1.17-1.28) adjusting for baseline treatment 
including statin medications, post- diagnosis. Significant disparities in statin use 
were found in gender, race/ethnicity, and age. Males were more likely than females 
to receive statins. Asians also higher statin usage compared to Caucasians, and 
those aged 65-74 were more likely use treatment compared to patients older than 
75. ConClusions: Statin treatment usage patterns vary significantly among newly 
diagnosed older adults with new onset diabetes.
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objeCtives: The availability of enhanced Medicare Part D plans with generic-only 
coverage during the coverage gap (i.e. donut hole) and the genericization of pravas-
drugs in Croatia from 2000-2013 and to identify the rate of the generic drugs 
usage as well as the average price for 1 DDD. Methods: Data on the consump-
tion have been obtained from the database IMS (International Medical Statistics) 
for Croatia. According to the World Health Organization Collaborating Centre for 
Drugs Statistics Methodology annual volumes of drugs are presented in defined 
daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data 
are presented in Euros (€ ). Results: The total usage of Agents acting on RAS 
(C09 subgroup) in constantly increasing from 58,56 DDD/1000 inh/day in 2000. to 
199,88 DDD/1000 inh/day in 2013. In 14-year period, consumption in DDD/1000 
inh/day increased 241%, while the financial expenditure in same period increased 
74% (from 28,8 mil € in 2000 to 50,3 mil € in 2013), but achieved its maximum 
in 2008 (57,7 mil € ). The consumption share of generic Agents acting on RAS 
decreased from 90% in 2000 to 56% in 2006, then constantly increasing to 68% 
in 2013. ConClusions: Drugs prescription patterns among Agents acting on 
RAS have been changing during the 14-year period in Croatia. Impact of gener-
ics decreased until 2006. Because of introduction of new original drugs, but the 
national healthare policy promoting generics resulted in their increase of share 
up to 2013. Although the generic drugs usage in C09 subgroup is relatively high, it 
should be further supported and promoted.
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objeCtives: Identify patients who were being treated for hypertension with conven-
tional release verapamil (CRV), notify the responsible of health care about cardiovas-
cular risk to which they are exposed and achieve a reduction in the number of patients 
who use it. Methods: A quasi-experimental prospective before and after study with-
out a control group was conducted in 7289 patients diagnosed with hypertension to 
be found in treatment with CRV, between October 1, 2012 and December 31, 2012 in 
8 Colombian cities from a database for dispensing medicines. Socio-demographic 
and pharmacological variables were evaluated. A total of 108 educational interven-
tions were performed for those responsible for health care, and evaluated within 
three months the proportion of suspension of the prescriptions of CRV. Multivariate 
analysis was performed using SPSS 22.0. Results: The mean age of patients was 
67.9±11.8 years (range: 26-96 years). 70.6% were men. Was obtained that discontinue 
treatment with CRV a total of 1922 patients (26.3% of users), distributed as follows: 
1160 (60.4%) were the presentation of 120 mg, while 762 (39.6%) the 80 mg. The vari-
able being treated in the city of Medellín (OR: 17.6; 95% CI: 11.949 to 25.924; p < 0.001) 
was associated statistically significant with change of CRV by another antihyperten-
sive. ConClusions: We found relative moderate adherence to recommendations 
about the proper use of CRV in hypertensive patients. Must be reinforced intervention 
programs that reduce inappropriate prescribing of potential risks to patients of insur-
ance companies and cities where the change was not achieved.
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objeCtives: This analysis provides an in-depth look at the number and types of 
drugs used by seniors, and compares drug use among seniors living in long-term 
care (LTC) facilities and those living in the community. Methods: Data from the 
National Prescription Drug Utilization Information System (NPDUIS) Database, 
housed at CIHI, as submitted by eight Provincial drug programs and one Federal 
drug program in Canada, including drug claims for approximately 70% of Canadian 
seniors. Results: In 2012, nearly two-thirds (65.9%) of seniors had claims for 5 or 
more drug classes, and more than one-quarter (27.2%) of seniors had claims for 10 
or more drug classes. The proportion of seniors age 85 and older with claims for 10 
or more drug classes (39.3%) was double that of seniors age 65 to 74 (20.0%). Six of 
the 10 drug classes most commonly used by seniors were cardiovascular-related. 
The most commonly used drug class was statins, which are used by almost half 
of seniors (46.6%). More than one-third of seniors (38.9%) had claims for a drug on 
the Beers list—a list of drugs identified as potentially inappropriate to prescribe 
to seniors. More than half of seniors living in LTC facilities were using 10 or more 
different drug classes (60.9%), more than double the proportion among seniors liv-
ing in the community (26.1%). In LTC facilities benzodiazepine use was double the 
rate, antidepressant use triple the rate and antipsychotic use nine times the rate 
among seniors living in the community. ConClusions: Findings suggest a high 
proportion of seniors, particularly those living in LTC facilities may be at risk for 
drug interactions and other adverse events due to the number of medications they 
are taking. This illustrates the importance of medication management strategies for 
seniors, and the need for communication between health care providers regarding 
seniors’ drug regimens.
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objeCtives: Generic Drug Discount Programs (GDDPs), introduced in 2006 and 
offered by the majority of retail pharmacies nationwide, offer many commonly 
used medications at low out-of-pocket prices. The objective of this study was to 
estimate the proportion of prescription claims filled using a GDDP for four com-
monly used medications. Methods: The Medical Expenditure Panel Survey annual 
prescribed medicines event file, a nationally representative sample that contains 
detailed drug information including payments made by private insurance, Medicaid/
Medicare, out-of-pocket, and other sources, was used for this study. Annual prescrip-
tion claim records, including new fills and refills of any quantity dispensed, were 
